Keywords: eyetech/pfizer, macugen, shows, long-term, benefits, neovascular, amd
Eyetech/Pfizer's Macugen shows long-term benefits for neovascular AMD
Article | 01 November 2004
New results have been released which suggest that the benefits of Eyetech Pharmaceuticals/Pfizer's Macugen (pegaptanib sodium) in treating patients ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
